Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

Table 3 EGFR point mutations

#	Sex	Ethnicity	Smoking Status	Source Tissue	Response¹	Exon	CDS Mutation	Amino Acid	Previously Documented
44	F	Asian	N	Pleura	PR	20	G2549 > TT C2691 > CT	S768I L815L	[32–35] none
11	F	Asian	Unk.	Lung	PR	20	G2566 > TT*	V774L	V774M [35, 36]
28	M	Caucasian	Y	Brain	SD	20	G2581 > AG	G779S	G779F [36]
35	F	Caucasian	Unk.	Brain	SD	20	G2703 > GA	V819V	[37]
47	F	Asian	N	Lung	SD	21	T2573 > GG	L858R	[5-7, 13, 15, 35, 38, 39]

Point mutations detected in EGFR exons 20 and 21. All samples were classified as adenocarcinoma based on histology. Point mutations altering V774 and G779 have been previously documented to result in amino acid substitutions different than those found in this study.
* = no mutations detected in normal tissue remaining after microdissection
1 = response as measured radiographically and defined by SWOG modification of the WHO criteria [20].
PD = progressive disease, SD = stable disease, PR = partial response, Unk. = Unknown